To date, the prevalence of LOXHD1-associated HL in relatively larger NSHL cohorts with more than 50 patients has been reported only in seven countries, ranging from 0.365 to 3.28% (Figure 2). This evidence concerns the gene LOXHD1 and Hodgkins lymphoma.